MetaVia to present Phase 1 data on dual GLP‑1/glucagon agonist DA‑1726 at Precision Liver Symposium
MetaVia Inc. announced that an abstract on its Phase 1 multiple ascending‑dose trial of DA‑1726 has been accepted for an oral presentation at the Precision Liver Symposium on 4 Nov 2026 in Denver. The presentation, titled “DA‑1726, a Dual GLP‑1 and Glucagon Receptor Agonist, Leads to Significant Reduction in MRI‑PDFF and Weight Loss with Relative Preservation of Lean Mass,” will be delivered by Chief Medical Officer Sarah Browne, M.D. at 1:35 p.m. MT. The 32 mg dose in the trial showed weight‑loss, glucose‑control and waist‑circumference reductions, plus improvements in hepatic steatosis and liver stiffness measures.
Why it matters
The company notes that the forthcoming data could influence investor perception of DA‑1726’s clinical promise and affect MetaVia’s share price (the company’s filing does not contain analyst forecasts).
Key facts
- 1MetaVia’s abstract on Phase 1 data for DA‑1726 was accepted for an oral presentation at the Precision Liver Symposium 2026. prnewswire.com
- 2The symposium will be held on 4 Nov 2026 in Denver, Colorado, with the presentation at 1:35 p.m. MT at the Hilton Denver City Center. prnewswire.com
- 3Sarah Browne, M.D., Chief Medical Officer of MetaVia, is the presenting author. prnewswire.com
- 4In the Phase 1 multiple ascending‑dose trial, the 32 mg dose of DA‑1726 demonstrated weight loss, glucose control, waist‑circumference reduction and improvements in non‑invasive measures of hepatic steatosis and liver stiffness. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.